PT1419151E - Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições - Google Patents

Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições Download PDF

Info

Publication number
PT1419151E
PT1419151E PT2759342T PT02759342T PT1419151E PT 1419151 E PT1419151 E PT 1419151E PT 2759342 T PT2759342 T PT 2759342T PT 02759342 T PT02759342 T PT 02759342T PT 1419151 E PT1419151 E PT 1419151E
Authority
PT
Portugal
Prior art keywords
chrystals
ylidene
carboxamide
diethylamino
indole
Prior art date
Application number
PT2759342T
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas J Fleck
Michael Hawley
Stephen P Prescott
Mark T Maloney
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1419151(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of PT1419151E publication Critical patent/PT1419151E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
PT2759342T 2001-08-15 2002-08-13 Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições PT1419151E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
PT1419151E true PT1419151E (pt) 2014-03-27

Family

ID=23211067

Family Applications (2)

Application Number Title Priority Date Filing Date
PT2759342T PT1419151E (pt) 2001-08-15 2002-08-13 Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições
PT16196036T PT3168218T (pt) 2001-08-15 2002-08-13 Um cristal compreendendo um sal de ácido l-málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3h-indol- 3-ilideno)metil]-2,4-dimetil-1h-pirrol-3-carboxamida para utilização como um medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT16196036T PT3168218T (pt) 2001-08-15 2002-08-13 Um cristal compreendendo um sal de ácido l-málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3h-indol- 3-ilideno)metil]-2,4-dimetil-1h-pirrol-3-carboxamida para utilização como um medicamento

Country Status (42)

Country Link
US (2) US20030069298A1 (enExample)
EP (3) EP3168218B1 (enExample)
JP (1) JP4159988B2 (enExample)
KR (1) KR100639281B1 (enExample)
CN (2) CN100364991C (enExample)
AP (1) AP1660A (enExample)
AR (1) AR036261A1 (enExample)
AU (1) AU2002324684B2 (enExample)
BG (1) BG108553A (enExample)
BR (1) BR0211612A (enExample)
CA (1) CA2455050C (enExample)
CO (1) CO5550431A2 (enExample)
CU (1) CU23713B7 (enExample)
CY (1) CY1121552T1 (enExample)
CZ (1) CZ2004196A3 (enExample)
DK (2) DK1419151T3 (enExample)
EA (1) EA006445B9 (enExample)
EC (1) ECSP044975A (enExample)
ES (3) ES2453164T3 (enExample)
GE (1) GEP20063777B (enExample)
HR (1) HRP20040112B1 (enExample)
HU (1) HU229206B1 (enExample)
IL (1) IL160097A0 (enExample)
IS (1) IS7147A (enExample)
MA (1) MA27058A1 (enExample)
ME (1) ME00414B (enExample)
MX (1) MXPA04001452A (enExample)
MY (1) MY139383A (enExample)
NO (1) NO326508B1 (enExample)
NZ (1) NZ531232A (enExample)
OA (1) OA12650A (enExample)
PL (1) PL216524B1 (enExample)
PT (2) PT1419151E (enExample)
RS (1) RS53251B (enExample)
SI (2) SI1419151T1 (enExample)
SK (1) SK902004A3 (enExample)
TN (1) TNSN04028A1 (enExample)
TR (1) TR201900509T4 (enExample)
TW (1) TWI269796B (enExample)
UA (1) UA76483C2 (enExample)
WO (1) WO2003016305A1 (enExample)
ZA (1) ZA200400706B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1419151T1 (sl) 2001-08-15 2014-04-30 Pharmacia & Upjohn Company Llc Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
MXPA06003661A (es) * 2003-10-02 2006-06-05 Pharmacia & Upjohn Co Llc Sales y polimorfos de un compuesto de indolinona sustituido con pirrol.
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
PL1773811T3 (pl) * 2004-07-22 2011-02-28 Lilly Co Eli Krystaliczny zmienny hydrat soli hemibursztynianowej (s)-6-(4-(2-((3(9h-karbazol-4-iloksy)-2-hydroksypropylo)amino)-2-metylopropylo)fenoksy)-3-pirydynokarboksy amidu
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
RU2399619C2 (ru) * 2005-09-19 2010-09-20 Пфайзер Продактс Инк. Твердые солевые формы замещенного пирролом 2-индолинона
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
WO2009067686A2 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
CN101939314B (zh) * 2007-12-12 2014-04-02 麦迪凯姆股份公司 3-吡咯取代的2-吲哚酮的多晶型物
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2252607A2 (en) * 2008-02-21 2010-11-24 Generics [UK] Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
CA2720164A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
CN102066362B (zh) 2008-05-23 2014-07-30 上海医药工业研究院 二氢吲哚酮衍生物
SI2313371T1 (sl) * 2008-06-13 2013-02-28 Medichem, S.A. Postopek za pripravo soli 3-pirol substituirane 2-indolinonske jabolčne kisline
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・（ユーケー）・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
CA2731605A1 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
EP2342195B1 (en) * 2008-07-24 2014-09-10 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
CA2734965A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
CN102197034A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的新型多晶型物及其制备方法
CN102177155A (zh) * 2008-10-10 2011-09-07 麦迪凯姆股份公司 一种3-吡咯取代的2-吲哚酮苹果酸盐的制备工艺
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2896618A1 (en) 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
WO2011033472A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
WO2011107919A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
CA2793359A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CN104114550A (zh) 2012-03-23 2014-10-22 劳拉斯实验室私人有限公司 制备舒尼替尼及其酸加成盐的改进的方法
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
EP3524262A1 (en) 2013-11-01 2019-08-14 Pfizer Inc Vectors for expression of prostate-associated antigens
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
US20220192989A1 (en) * 2019-04-18 2022-06-23 Meter Health, Inc. Methods and compositions for treating respiratory arrhythmias
EP3958845A1 (en) 2019-04-25 2022-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225055B1 (en) 1990-10-15 2006-05-29 Pfizer Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
CA2097208C (en) 1992-06-05 2005-02-08 Raymond Baker The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
ATE202109T1 (de) * 1993-03-12 2001-06-15 Upjohn Co Kristallines ceftiofur (freie säure)
US5665878A (en) * 1994-08-31 1997-09-09 Eli Lilly And Company Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives
DE19503966C2 (de) * 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6066647A (en) * 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
SI9720059B (sl) 1996-08-14 2011-11-30 Searle & Co Kristalinična oblika 4-/5-metil-3-fenilizoksazol-4-il/benzensulfonamida
CN1104378C (zh) * 1996-12-25 2003-04-02 日本化药株式会社 顺铂细粉及其制备方法
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
PL200710B1 (pl) 1998-06-19 2009-01-30 Teijin Pharma Ltd Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania
DE69906152T2 (de) * 1998-12-17 2004-02-12 F. Hoffmann-La Roche Ag 4-alkenyl (und alkinyl)oxoindole als inhibitoren cyclinabhängiger kinasen, insbesondere cdk2
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
JP5336686B2 (ja) * 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
HRP20020751B1 (hr) * 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
US6316672B1 (en) * 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
SI1419151T1 (sl) 2001-08-15 2014-04-30 Pharmacia & Upjohn Company Llc Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh
EP2252607A2 (en) 2008-02-21 2010-11-24 Generics [UK] Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
ZA200400706B (en) 2005-05-25
BG108553A (bg) 2005-04-30
RS53251B (sr) 2014-08-29
NO326508B1 (no) 2008-12-15
OA12650A (en) 2006-06-19
EP3168218B1 (en) 2018-11-14
HU229206B1 (en) 2013-09-30
UA76483C2 (en) 2006-08-15
KR100639281B1 (ko) 2006-10-31
TR201900509T4 (tr) 2019-02-21
EP1419151B1 (en) 2014-02-26
PT3168218T (pt) 2019-01-11
MY139383A (en) 2009-09-30
US7435832B2 (en) 2008-10-14
AP1660A (en) 2006-09-09
JP4159988B2 (ja) 2008-10-01
ECSP044975A (es) 2004-03-23
HUP0700036A2 (en) 2008-10-28
AR036261A1 (es) 2004-08-25
IL160097A0 (en) 2004-06-20
CN100364991C (zh) 2008-01-30
CY1121552T1 (el) 2020-05-29
SI3168218T1 (sl) 2019-05-31
EA006445B1 (ru) 2005-12-29
ES2705063T3 (es) 2019-03-21
EP3168218A1 (en) 2017-05-17
PL216524B1 (pl) 2014-04-30
EP2332934B1 (en) 2017-03-01
SI1419151T1 (sl) 2014-04-30
DK1419151T3 (da) 2014-03-31
SK902004A3 (sk) 2005-03-04
HK1088008A1 (zh) 2006-10-27
CN100439360C (zh) 2008-12-03
RS10304A (sr) 2007-02-05
CU20040029A7 (es) 2008-03-14
IS7147A (is) 2004-02-10
CO5550431A2 (es) 2005-08-31
ES2623094T3 (es) 2017-07-10
GEP20063777B (en) 2006-03-27
WO2003016305A1 (en) 2003-02-27
ME00414B (me) 2011-10-10
HK1066542A1 (en) 2005-03-24
MXPA04001452A (es) 2004-05-20
AU2002324684B2 (en) 2006-10-05
EP2332934A1 (en) 2011-06-15
HRP20040112B1 (en) 2012-03-31
PL368317A1 (en) 2005-03-21
KR20040030074A (ko) 2004-04-08
CN1543462A (zh) 2004-11-03
MA27058A1 (fr) 2004-12-20
NZ531232A (en) 2004-11-26
CN1789264A (zh) 2006-06-21
CA2455050C (en) 2007-02-20
JP2005503386A (ja) 2005-02-03
EA006445B9 (ru) 2017-02-28
CZ2004196A3 (cs) 2005-01-12
ES2453164T3 (es) 2014-04-04
EP1419151A1 (en) 2004-05-19
EA200400183A1 (ru) 2004-08-26
TNSN04028A1 (fr) 2006-06-01
TWI269796B (en) 2007-01-01
CA2455050A1 (en) 2003-02-27
US20030069298A1 (en) 2003-04-10
DK3168218T3 (en) 2019-01-14
AP2004002976A0 (en) 2004-03-31
HRP20040112A2 (en) 2004-06-30
US20070191458A1 (en) 2007-08-16
NO20041054L (no) 2004-03-12
BR0211612A (pt) 2004-08-24
CU23713B7 (es) 2011-10-05

Similar Documents

Publication Publication Date Title
IL160097A0 (en) Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
IL189359A0 (en) Novel process for the synthesis of 5 - (4 - fluorophenyl) - 1 - [2 - ((2r, 4r)- 4 - hydroxy - 6 - oxo -tetrahydro - pyran - 2 - yl) - ethyl] - 2 - isopropyl- 4 - phenyl - 1h - pyrrole - 3 - carboxylic acid phenylamide
EP1619180A4 (en) CASR ANTAGONIST
IL156055A (en) Crystal form viii of atorvastatin hemi- calcium, processes for its preparation and pharmaceutical composition comprising atorvastatin hemi-calcium form viii
HUP0300148A3 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2006025070A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
IL190218A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
HUP0203841A3 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
HUP0402554A3 (en) Condensated heterocyclic succinimide compounds, their use, process for the preparation of some of them and pharmaceutical compositions containing the compounds
ZA200101821B (en) Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection.
IL185035A0 (en) Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
SI1600441T1 (sl) Kristalna oblika lerkanidipin hidroklorida za uporabo kot sredstvo proti hipertenziji
EE05242B1 (et) 5-kloro-3-(4-metaansulfonlfenl)-6'-metl[2,3']bipridinli polmorfne vorm, selle valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
HUP0402486A3 (en) Nitrogen containing heterocyclic compounds as peroxisome proliferator activated receptor agonists, their use and pharmaceutical compositions cointaining them
HUP0401694A3 (en) Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use
ZA200500203B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
PL367128A1 (en) Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
HUP0200608A3 (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors and pharmaceutical compositions containing them
DE50305374D1 (de) Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
PL375415A1 (en) Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
AU1479800A (en) Procedure for synthesis of N-(2(((5-((dialkilamino) methyl)-2- furanyl) methyl)thyo) ethyl)-N'- alkyl-2-nitro1,1 alkenediamines and their hydrochlorides
HUP0402388A3 (en) Use of n-(indolecarbonyl-)piperazine derivatives for preparation of pharmaceutical compositions
AU2002245958A1 (en) Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications